logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Fulltext. Prior to use of estrogen replacement therapy, are users healthier than nonusers ? Commentary. Authors'reply.

    Article - En anglais

    Fulltext.

    Observational studies have demonstrated that women who have used postmenopausal estrogen replacement therapy (ERT) are at reduced risk of coronary heart disease.

    The authors examined whether premenopausal women who subsequently elected to use ERT during menopause had a better cardiovascular risk factor profile prior to use than did nonusers.

    A total of 541 premenopausal women had their cardiovascular risk factors and psychosocial characteristics evaluated at study entry.

    After approximately 8 years, 355 women had become postmenopausal, and 157 women reported ERT use during the follow-up period (mean=93.4 months).

    The authors compared the premenopausal characteristics of users with those of nonusers.

    Relative to nonusers, ERT users were better educated (63 vs. 81% with at least some college), and prior to the use of ERT had higher levels of high density lipoprotein (HDL) cholesterol (1.49 vs. 1.59 mmol/liter), HDL2 (0.50 vs. 0.57 mmol/liter), HDL3 (0.98 vs. 1.02 mmol/liter), leisure physical activity (5,122 vs. 7,158 Kjoules), and alcohol intake (7.5 vs. 9.7 g/day), and lower levels of apolipoprotein B (0.97 vs. 0.90 g/liter), systolic blood pressure (112.1 vs. 107.1 mmHg) and diastolic blood pressure (73.8 vs. 71.4 mmHg), weight (68.5 vs. 64.2 kg), and fasting insulin (9.10 vs. 7.66 muU/liter).

    Prior to use of ERT, in comparison with nonusers, subsequent users reported on standardized questionnaires that they more often exhibited Type A behavior, were more...

    Mots-clés Pascal : Oestrogène, Chimiothérapie, Traitement substitutif, Ménopause, Epidémiologie, Cardiopathie coronaire, Facteur risque, Femme, Homme, Préménopause, Postménopause, Etude comparative, Pennsylvanie, Etats Unis, Amérique du Nord, Amérique, Hormone stéroïde sexuelle, Appareil circulatoire pathologie

    Mots-clés Pascal anglais : Estrogen, Chemotherapy, Replacement therapy, Menopause, Epidemiology, Coronary heart disease, Risk factor, Woman, Human, Premenopause, Postmenopause, Comparative study, Pennsylvania, United States, North America, America, Sex steroid hormone, Cardiovascular disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0254127

    Code Inist : 002B02O. Création : 199608.